397030 — AprilBio Co Income Statement
0.000.00%
Last trade - 00:00
- KR₩380bn
- KR₩322bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 150 | 0 | 23,396 | 200 | 0 |
Cost of Revenue | |||||
Gross Profit | 150 | 0 | 23,396 | — | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3,072 | 9,188 | 18,950 | 11,664 | 13,385 |
Operating Profit | -2,922 | -9,188 | 4,446 | -11,464 | -13,385 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -4,776 | -10,344 | -52,713 | -8,959 | -14,130 |
Provision for Income Taxes | |||||
Net Income After Taxes | -4,823 | -10,220 | -52,713 | -8,959 | -14,130 |
Net Income Before Extraordinary Items | |||||
Net Income | -4,823 | -10,220 | -52,713 | -8,959 | -14,130 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4,823 | -10,220 | -52,713 | -8,959 | -14,130 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -229 | -486 | -2,507 | -458 | -661 |
Dividends per Share |